Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Change in Acquisitions & Divestments (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Change in Acquisitions & Divestments data on record, last reported at $111.5 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 27.59% year-over-year to $111.5 million; the TTM value through Dec 2025 reached $596.3 million, up 18.85%, while the annual FY2025 figure was $596.3 million, 18.85% up from the prior year.
  • Change in Acquisitions & Divestments reached $111.5 million in Q4 2025 per CLDX's latest filing, down from $116.9 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $195.0 million in Q1 2025 and bottomed at $13.0 million in Q3 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $93.7 million, with a median of $84.6 million recorded in 2022.
  • The widest YoY moves for Change in Acquisitions & Divestments: up 562.38% in 2022, down 64.3% in 2022.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $45.9 million in 2021, then surged by 91.09% to $87.8 million in 2022, then fell by 19.26% to $70.9 million in 2023, then soared by 117.2% to $154.0 million in 2024, then dropped by 27.59% to $111.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $111.5 million in Q4 2025, $116.9 million in Q3 2025, and $172.8 million in Q2 2025.